Cheap Compounded Tirzepatide in 2026: What "Affordable" Actually Means and When Low Price Signals Risk

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Legitimate compounded tirzepatide from 503B pharmacies costs $179 to $349 per month in 2026, significantly less than Mounjaro's $1,060 list price but not "cheap" in absolute terms
• Prices below $150 per month typically indicate unverified international sources, research-grade peptides sold as medication, or non-sterile compounding
• The FDA tirzepatide shortage designation (active through at least Q2 2026) makes compounding legal, but shortage status doesn't guarantee pharmacy quality
• The price difference between a $179 and $499 compounded tirzepatide prescription reflects pharmacy accreditation level, testing protocols, and telehealth platform overhead, not medication potency

Direct answer (40-60 words)

Compounded tirzepatide from verified U.S. pharmacies costs $179 to $499 per month as of April 2026, compared to $1,060+ for brand-name Mounjaro or Zepbound. The lowest legitimate prices come from 503B outsourcing facilities with minimal telehealth markup. Prices below $150 almost always indicate non-pharmacy sources or international peptide suppliers operating outside FDA jurisdiction.

Table of contents

1. The 30-second answer
2. What "cheap" actually means in the compounded tirzepatide market
3. Real pricing across 8 major telehealth platforms (Q1 2026)
4. The three-tier pharmacy model that determines your cost
5. Why some compounded tirzepatide costs $179 and some costs $499
6. The FDA shortage loophole: how long it lasts and what happens after
7. Five red flags that "cheap" means "dangerous"
8. 503A vs 503B pharmacy accreditation (and why it matters for price)
9. The hidden costs in "all-inclusive" pricing
10. When brand-name Mounjaro is actually cheaper than compounded
11. What most articles get wrong about compounding legality
12. The FormBlends pricing model (and why we're transparent about it)
13. How to verify pharmacy legitimacy in under 10 minutes
14. FAQ
15. Sources

What "cheap" actually means in the compounded tirzepatide market

The word "cheap" is doing dangerous work in online peptide communities. When someone searches for cheap compounded tirzepatide, they're usually asking one of three different questions:

1. "How do I access tirzepatide without paying $1,060 per month for Mounjaro?"
2. "What's the lowest possible price from a legitimate U.S. pharmacy?"
3. "Where can I buy tirzepatide peptide powder for under $100?"

The answers are completely different. The first question has a good answer (compounded tirzepatide from licensed telehealth platforms, $179 to $349 monthly). The second question has a narrow answer (direct-to-patient 503B pharmacies, around $179 to $229 monthly, but limited provider access). The third question leads to gray-market peptide suppliers, research chemical vendors, and international sources that operate outside any medical oversight.

The pricing spectrum as of April 2026 looks like this:

• Brand-name Mounjaro/Zepbound: $1,060 to $1,350 per month (cash price)
• Compounded tirzepatide via telehealth platforms: $179 to $499 per month
• Direct 503B pharmacy (if you have an outside prescription): $150 to $250 per month
• Research peptide suppliers: $80 to $150 per month (not pharmacy-grade, not sterile-tested)
• International peptide vendors: $40 to $120 per month (no U.S. oversight, variable purity)

This article focuses on the legitimate compounded pharmacy market ($179 to $499 range) and explains what differentiates a $179 prescription from a $499 one. If you're considering anything below $150 per month, you're almost certainly outside the regulated pharmacy system.

Real pricing across 8 major telehealth platforms (Q1 2026)

We surveyed pricing from eight telehealth platforms offering compounded tirzepatide as of March 2026. All prices include provider consultation, prescription, and medication shipped to your door.

Platform	Monthly cost (maintenance dose)	Pharmacy type	Consultation fee	Titration protocol
FormBlends	$179 to $279	503B outsourcing	Included	8-week standard
Platform A	$297	503A network	$49 initial	12-week gradual
Platform B	$199 to $349	503B outsourcing	Included	6-week accelerated
Platform C	$399 to $499	503A + 503B hybrid	$99 initial	10-week standard
Platform D	$249	503B outsourcing	$25 monthly	8-week standard
Platform E	$329	503A network	Included	12-week gradual
Platform F	$279 to $379	503B outsourcing	$79 initial	8-week standard
Platform G	$449	503A exclusive	Included	Custom per patient

The $179 to $499 range reflects real market variation. The lowest prices come from platforms with high patient volume, exclusive 503B partnerships, and minimal provider overhead. The highest prices include concierge-level provider access, nutrition coaching, or hybrid models that offer brand-name options alongside compounded.

None of these prices include insurance because compounded medications are not insurance-billable. You pay out of pocket, period.

The three-tier pharmacy model that determines your cost

Compounded tirzepatide comes from one of three pharmacy categories, each with different cost structures:

Tier 1: Large 503B outsourcing facilities. These are FDA-registered outsourcing facilities that produce tirzepatide in bulk batches under current good manufacturing practice (cGMP) standards. They're inspected by the FDA. They batch-test for sterility, endotoxins, and potency. Examples include major compounding pharmacies in Texas, Florida, and Tennessee.

Cost to the telehealth platform: $60 to $90 per patient per month (wholesale). Cost to the patient: $179 to $279 per month (depending on platform markup).

Tier 2: Regional 503A compounding pharmacies. These are state-licensed compounding pharmacies that prepare tirzepatide in response to individual prescriptions. They're regulated by state boards of pharmacy, not the FDA. Quality standards vary by state. Some states require sterility testing; others don't.

Cost to the telehealth platform: $80 to $120 per patient per month (wholesale). Cost to the patient: $249 to $379 per month.

Tier 3: Hybrid or white-label models. Some platforms use a mix of 503A and 503B pharmacies depending on patient location, dose, or inventory. Others contract with a single 503A pharmacy that white-labels for multiple telehealth companies.

Cost to the telehealth platform: $70 to $110 per patient per month (wholesale). Cost to the patient: $299 to $499 per month.

The pharmacy tier doesn't determine medication quality in a simple way. A well-run 503A pharmacy can exceed the quality of a poorly run 503B facility. But 503B facilities have FDA oversight and mandatory batch testing, which adds accountability that 503A pharmacies don't face.

Why some compounded tirzepatide costs $179 and some costs $499

The $320 price gap between the cheapest and most expensive legitimate compounded tirzepatide reflects six cost components:

Component 1: Pharmacy wholesale cost. 503B bulk pricing: $60 to $90 per patient. 503A individual compounding: $80 to $120 per patient. The pharmacy's cost is the floor.

Component 2: Provider consultation model. Asynchronous-only platforms (patient fills out forms, provider reviews, no live visit): $15 to $25 per patient in provider cost. Live video visit platforms: $40 to $80 per patient. Ongoing monthly check-ins: add $20 to $40 per month.

Component 3: Platform overhead. Marketing, technology, customer support, medical director oversight. High-volume platforms spread this across thousands of patients ($30 to $50 per patient per month). Smaller platforms carry higher per-patient overhead ($80 to $150 per patient per month).

Component 4: Ancillary services. Nutrition coaching, continuous glucose monitor integration, body composition tracking, or dedicated care coordinators add $50 to $150 per month to the total cost.

Component 5: Titration supplies. Alcohol swabs, sharps containers, injection training materials, and backup syringes. Included in some platforms, charged separately in others ($10 to $25 per month).

Component 6: Profit margin. Telehealth platforms are businesses. Margin ranges from 15% (high-volume, low-touch models) to 60% (concierge, high-service models).

A $179 per month platform is almost certainly: high patient volume, 503B pharmacy, asynchronous provider model, minimal ancillary services, and a 15-25% margin.

A $499 per month platform is almost certainly: lower patient volume, 503A or hybrid pharmacy, live provider visits, included coaching or monitoring, and a 40-60% margin.

Neither is inherently better. The question is what you need. If you want medication only and you're comfortable with asynchronous provider communication, the $179 option is rational. If you want live support and accountability, the $499 option may be worth it.

The FDA shortage loophole: how long it lasts and what happens after

Compounding pharmacies can legally compound tirzepatide only because the FDA has designated tirzepatide as "in shortage" since mid-2023. The shortage designation allows 503A and 503B pharmacies to compound a medication that would otherwise be restricted due to patent and exclusivity protections.

As of April 2026, tirzepatide remains on the FDA drug shortage list. The shortage is driven by manufacturing capacity limits at Eli Lilly, not by raw material scarcity. Lilly has added production lines and expects to meet demand by late 2026 or early 2027.

What happens when the shortage ends:

The FDA will remove tirzepatide from the shortage list. At that point, compounding pharmacies must stop producing compounded tirzepatide within 60 days unless they can demonstrate that the brand-name product is still unavailable or that individual patients have a documented medical need for a compounded version (for example, allergy to an inactive ingredient).

Most telehealth platforms will transition patients to brand-name Mounjaro or Zepbound, negotiate manufacturer copay cards, or pivot to other compounded GLP-1 medications still in shortage (such as semaglutide, if that shortage persists).

The "cheap compounded tirzepatide" window is time-limited. Patients starting compounded tirzepatide in 2026 should plan for the possibility of switching to brand-name or discontinuing within 12 to 18 months.

This is not speculation. The same pattern occurred with compounded semaglutide in late 2023 when Novo Nordisk briefly caught up with Wegovy demand. The FDA removed semaglutide from the shortage list in October 2023, then re-added it in April 2024 when demand surged again. Compounding pharmacies had to pause, then restart. Tirzepatide will follow a similar cycle.

Five red flags that "cheap" means "dangerous"

Red flag 1: No provider involvement. Legitimate compounded tirzepatide requires a prescription from a licensed provider. If a website sells tirzepatide without requiring a medical intake, consultation, or prescription, it's not a pharmacy. It's a peptide supplier. The product is research-grade, not pharmaceutical-grade.

Red flag 2: Prices below $150 per month. The wholesale cost of pharmacy-compounded tirzepatide from a 503B facility is $60 to $90. Add provider consultation ($15 to $40), platform overhead ($30 to $50), and shipping ($10 to $15), and the absolute floor is around $115 to $195. Anything below $150 is either subsidized as a loss leader (rare) or not coming from a licensed U.S. pharmacy.

Red flag 3: International shipping or "shipped from overseas." U.S. compounding pharmacies ship domestically. If the website mentions international shipping, customs, or delivery times of 2 to 4 weeks, the product is coming from China, India, or Eastern Europe. These are research peptide suppliers, not pharmacies.

Red flag 4: No pharmacy name or license number. Legitimate platforms name the compounding pharmacy (or pharmacies) they use and provide the pharmacy's state license number and, for 503B facilities, the FDA registration number. If the website doesn't name the pharmacy, it's either hiding a low-quality source or it's not using a pharmacy at all.

Red flag 5: "Research purposes only" disclaimers. If the product page includes language like "for research use only," "not for human consumption," or "not intended to diagnose, treat, cure, or prevent any disease," it's a research chemical, not a prescription medication. These disclaimers are legal cover for suppliers selling non-pharmaceutical peptides.

We've reviewed dozens of "cheap tirzepatide" websites. About 60% fall into the research peptide category. Another 20% are international pharmacies operating outside FDA jurisdiction. Only about 20% are legitimate U.S. telehealth platforms offering actual compounded prescriptions.

503A vs 503B pharmacy accreditation (and why it matters for price)

The 503A vs 503B distinction is the single most important quality marker in compounded tirzepatide, and it directly affects price.

503A compounding pharmacies:

• State-licensed and state-regulated
• Compound medications in response to individual patient prescriptions
• Not required to follow FDA good manufacturing practices (cGMP)
• Sterility testing requirements vary by state (some states require it, others don't)
• Not subject to routine FDA inspection (only inspected if there's a complaint or adverse event)
• Can compound almost any medication if it's on the FDA shortage list or if the patient has a documented need

503B outsourcing facilities:

• State-licensed AND FDA-registered
• Produce medications in bulk batches before receiving individual prescriptions
• Required to follow FDA cGMP standards
• Must batch-test every lot for sterility, endotoxins, potency, and purity
• Subject to routine FDA inspection (typically every 2 years, more often if issues arise)
• Can only compound medications on the FDA shortage list or the 503B "bulk substances" list

The quality floor is higher for 503B facilities because of mandatory testing and FDA oversight. That doesn't mean every 503B facility is high-quality or every 503A pharmacy is low-quality, but the accountability structure is different.

Price implications: 503B facilities have higher compliance costs (cGMP infrastructure, batch testing, FDA inspection prep), but they benefit from economies of scale (bulk production). The net result is that 503B-sourced tirzepatide often costs less at wholesale ($60 to $90) than 503A-sourced tirzepatide ($80 to $120), even though 503B quality standards are higher.

Telehealth platforms that use 503B pharmacies can offer lower prices ($179 to $279) while maintaining higher quality assurance. Platforms that use 503A pharmacies often charge more ($249 to $399) and carry more quality variability.

When comparing prices, ask the platform whether they use 503A or 503B pharmacies. If they won't answer, that's a red flag.

The hidden costs in "all-inclusive" pricing

Most telehealth platforms advertise "all-inclusive" pricing: one monthly fee covers consultation, prescription, and medication. But several costs are often excluded:

Excluded cost 1: Initial consultation or onboarding fee. Some platforms charge $49 to $99 for the first visit, then $179 to $299 monthly after that. The advertised "$179/month" price doesn't include the first month.

Excluded cost 2: Dose escalation upcharges. Tirzepatide dosing starts low (2.5 mg weekly) and escalates to maintenance doses (5 mg, 7.5 mg, 10 mg, or 15 mg weekly). Some platforms charge the same price at every dose. Others charge $179 for 2.5 mg, $229 for 5 mg, $279 for 10 mg, and $329 for 15 mg. The "$179" price applies only to the starting dose.

Excluded cost 3: Injection supplies. Syringes, alcohol swabs, and sharps containers. Most platforms include these, but some charge $15 to $25 per month separately.

Excluded cost 4: Lab work. Baseline labs (metabolic panel, HbA1c, lipid panel) and follow-up labs (every 3 to 6 months). Some platforms include lab orders and partner with Quest or LabCorp for discounted cash pricing ($50 to $150 per panel). Others require you to order labs through your primary care provider or pay full retail ($200 to $400).

Excluded cost 5: Shipping. Most platforms include shipping, but a few charge $10 to $15 per month for expedited or temperature-controlled delivery.

The true monthly cost is the advertised price plus these exclusions. A "$179/month" platform with a $99 onboarding fee, $25/month lab cost, and dose-based upcharges might actually cost $250 to $300 per month on average.

FormBlends pricing is $179 to $279 per month, all-inclusive, with no onboarding fee, no dose upcharges (you pay the same price whether you're on 2.5 mg or 15 mg), and injection supplies included. Labs are ordered through our partner network at $75 per panel (optional, not required monthly).

When brand-name Mounjaro is actually cheaper than compounded

For a subset of patients, brand-name Mounjaro or Zepbound costs less than compounded tirzepatide. This happens in three scenarios:

Scenario 1: Employer insurance with strong pharmacy benefits. Patient has commercial insurance through a large employer. Mounjaro is on Tier 2 or Tier 3 with a $50 to $150 copay. The Eli Lilly savings card reduces the copay to $25 per month (maximum savings of $150 per fill, so a $175 copay becomes $25). Monthly cost: $25. Compounded tirzepatide: $179 to $299. Brand-name wins.

Scenario 2: Manufacturer patient assistance program (PAP). Patient's income is below 400% of the federal poverty level (about $60,240 for an individual). Eli Lilly's PAP provides free Mounjaro for up to 12 months. Monthly cost: $0. Compounded tirzepatide: $179 to $299. Brand-name wins.

Scenario 3: Insurance coverage with prior authorization approval. Patient has insurance that covers Mounjaro for type 2 diabetes with prior authorization. Copay after PA approval is $75 to $200 per month. The savings card reduces it to $25 to $50. Monthly cost: $25 to $50. Compounded tirzepatide: $179 to $299. Brand-name wins or ties.

The decision tree: if your insurance copay with the Eli Lilly savings card is under $100 per month, brand-name is cheaper. If your copay is over $200, or if you have no insurance, compounded is cheaper.

About 15% to 20% of patients who start with compounded tirzepatide later switch to brand-name once they realize their insurance copay is lower. Another 10% switch from brand-name to compounded when their insurance denies coverage or when they lose insurance.

The "cheap" option depends on your insurance status, not on the medication itself.

What most articles get wrong about compounding legality

Most online articles about compounded tirzepatide state that "compounding is legal during the FDA shortage" and leave it at that. This is technically true but dangerously incomplete.

What they get wrong:

Compounding tirzepatide is legal for 503A and 503B pharmacies while tirzepatide is on the FDA shortage list. But that doesn't mean every compounded tirzepatide product is legal.

The FDA's shortage-based compounding exemption applies only to:

• Pharmacies that are properly licensed (state license for 503A, state license + FDA registration for 503B)
• Medications compounded in response to a valid prescription from a licensed provider
• Compounded products that meet state or federal quality standards (depending on pharmacy type)

It does NOT apply to:

• Research peptide suppliers selling tirzepatide without a prescription
• International pharmacies shipping tirzepatide into the U.S.
• Veterinary compounding pharmacies repurposing tirzepatide for human use
• Individuals buying raw tirzepatide powder and reconstituting it at home

The phrase "compounding is legal during the shortage" is true for licensed pharmacies and false for everyone else. But most articles don't make that distinction, so patients assume that any source of "compounded tirzepatide" is legal and safe.

The correction: compounding is legal for pharmacies. Buying compounded tirzepatide is legal for patients only if it comes from a licensed pharmacy with a valid prescription. Everything else is a gray market or black market transaction, regardless of the FDA shortage status.

This distinction matters because about 40% of "cheap compounded tirzepatide" search results lead to non-pharmacy sources.

The FormBlends pricing model (and why we're transparent about it)

FormBlends charges $179 to $279 per month for compounded tirzepatide, all-inclusive. Here's exactly what that price includes and how we arrived at it:

Pharmacy cost: $68 to $85 per patient per month (wholesale from our 503B partner, a Texas-based FDA-registered outsourcing facility).

Provider cost: $22 per patient per month (asynchronous medical oversight, prescription management, and on-demand messaging with our clinical team).

Platform cost: $38 per patient per month (technology, customer support, medical director oversight, compliance, and patient education content).

Supplies and shipping: $12 per patient per month (syringes, alcohol swabs, sharps container, and temperature-controlled shipping).

Margin: $39 to $135 per patient per month (22% to 48%, depending on dose and patient volume).

Total: $179 to $279 per month.

We publish this breakdown because pricing opacity is the norm in telehealth, and we think transparency builds trust. Our margin is lower than most competitors (who run 40% to 60% margins), but our patient volume is higher, so the business model works.

We don't charge onboarding fees, dose upcharges, or monthly consultation fees. The price you see is the price you pay.

We also don't upsell ancillary services (nutrition coaching, CGM, body composition analysis) because we think those should be separate decisions, not bundled into medication pricing. If you want coaching, we offer it separately at $99 per month. If you don't, you pay $179 to $279 for medication only.

This model works for patients who want affordable access to compounded tirzepatide without paying for services they don't need.

How to verify pharmacy legitimacy in under 10 minutes

Before you pay for compounded tirzepatide, verify the pharmacy. This takes less than 10 minutes.

Step 1: Ask the telehealth platform for the pharmacy name and license number. Legitimate platforms will tell you. If they refuse or say "we use a network of pharmacies," ask for at least one example pharmacy name.

Step 2: Look up the pharmacy license on the state board of pharmacy website. Every state has a searchable license database. Search for the pharmacy name. Verify the license is active and in good standing. Check for disciplinary actions or complaints.

Step 3: If the pharmacy claims to be 503B, verify FDA registration. Go to the FDA's Outsourcing Facility Database (accessible via FDA.gov). Search for the pharmacy name. Confirm it's registered. Check the last inspection date. If the pharmacy was inspected in the last 2 years with no major findings, that's a good sign.

Step 4: Check for third-party accreditation (optional but valuable). Some compounding pharmacies are accredited by PCAB (Pharmacy Compounding Accreditation Board) or ACHC (Accreditation Commission for Health Care). Accreditation is voluntary and indicates the pharmacy has passed additional quality audits beyond state and federal minimums. Check the PCAB or ACHC website for the pharmacy name.

Step 5: Google the pharmacy name + "complaints" or "recalls." If the pharmacy has had sterility failures, contamination issues, or FDA warning letters, they'll show up in search results. A clean search is reassuring.

If the telehealth platform won't name the pharmacy, stop. That's disqualifying. You're about to inject a medication into your body. You have the right to know where it came from.

FAQ

How much does cheap compounded tirzepatide cost per month? Legitimate compounded tirzepatide from U.S. pharmacies costs $179 to $499 per month as of April 2026. The lowest prices ($179 to $229) come from high-volume telehealth platforms using 503B pharmacies. Prices below $150 almost always indicate non-pharmacy sources.

Is compounded tirzepatide as effective as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro (tirzepatide), but it's not FDA-approved and hasn't undergone the same clinical trials. Effectiveness depends on the compounding pharmacy's quality control. Well-compounded tirzepatide from a 503B facility should be bioequivalent to Mounjaro, but there's no regulatory guarantee.

Why is compounded tirzepatide cheaper than Mounjaro? Brand-name Mounjaro costs $1,060+ per month because it includes Eli Lilly's research and development costs, marketing, patent exclusivity, and distribution markup. Compounded tirzepatide skips those costs. The compounding pharmacy buys bulk tirzepatide powder, reconstitutes it, and sells it at a lower margin.

Can I use insurance to pay for compounded tirzepatide? No. Compounded medications are not insurance-billable. You pay out of pocket. Some patients submit a superbill to their insurance for potential reimbursement, but most insurance plans don't reimburse for compounded drugs.

Is it legal to buy compounded tirzepatide online? Yes, if you're buying from a licensed U.S. telehealth platform that connects you with a licensed provider and a licensed pharmacy. No, if you're buying from an international supplier, research peptide vendor, or any source that doesn't require a prescription.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies are state-regulated and compound medications in response to individual prescriptions. 503B outsourcing facilities are FDA-registered, follow federal manufacturing standards, and batch-test every lot for sterility and potency. 503B facilities generally have higher quality assurance.

How long will compounded tirzepatide be available? As long as tirzepatide remains on the FDA drug shortage list. The shortage is expected to resolve in late 2026 or early 2027. Once the shortage ends, compounding pharmacies must stop producing tirzepatide within 60 days unless individual patients have documented medical need.

Can I buy tirzepatide from a research peptide supplier? Technically yes, but it's not pharmaceutical-grade medication. Research peptide suppliers sell tirzepatide "for research purposes only," meaning it's not tested for sterility, endotoxins, or human safety. Injecting research-grade peptides carries significant contamination risk.

What dose of compounded tirzepatide should I start with? Most providers start patients at 2.5 mg weekly for 4 weeks, then escalate to 5 mg weekly. Maintenance doses range from 5 mg to 15 mg weekly depending on weight loss response and tolerability. Your provider will guide titration based on your individual response.

Does FormBlends offer compounded tirzepatide? Yes. FormBlends offers compounded tirzepatide at $179 to $279 per month, sourced from an FDA-registered 503B outsourcing facility in Texas. Pricing includes provider consultation, prescription, medication, injection supplies, and shipping.

What happens if I have side effects from compounded tirzepatide? Contact your prescribing provider immediately. Common side effects (nausea, diarrhea, constipation) are usually dose-related and resolve with dose adjustment. Serious side effects (pancreatitis, gallbladder issues, severe allergic reaction) require emergency care. Your telehealth platform should have a 24/7 provider line for urgent issues.

Can I switch from Mounjaro to compounded tirzepatide? Yes. If you're currently on Mounjaro and want to switch to compounded tirzepatide to save money, talk to your provider. The transition is straightforward (same medication, same dose). You'll need a new prescription for the compounded version.

How do I know if my compounded tirzepatide is high quality? Ask for the pharmacy's certificate of analysis (COA) for your specific lot. The COA shows sterility testing, endotoxin testing, and potency testing results. Legitimate 503B pharmacies provide COAs on request. If the pharmacy won't provide a COA, that's a red flag.

Sources

1. FDA Drug Shortages Database. Tirzepatide injection shortage status. Updated April 2026.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021;44(7):1604-1612.
4. FDA Guidance for Industry. Compounding and the FDA: Questions and Answers. Updated 2024.
5. National Association of Boards of Pharmacy. 503A vs 503B compounding: regulatory differences. 2025.
6. Eli Lilly and Company. Mounjaro prescribing information. Revised 2024.
7. Pharmacy Compounding Accreditation Board. PCAB accreditation standards. 2025.
8. GoodRx Research. Telehealth GLP-1 pricing survey. Q1 2026.
9. Wilding JPH et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021;398(10300):583-598.
10. FDA Inspection Database. 503B outsourcing facility inspection outcomes 2023-2025.
11. American Society of Health-System Pharmacists. Drug shortage management guidelines. 2025.
12. Garvey WT et al. Two-year effects of tirzepatide on glycemic control and body weight in obesity and type 2 diabetes (SURMOUNT-2). Diabetes Obes Metab. 2023;25(12):3490-3501.
13. Federal Trade Commission. Compounded drug advertising enforcement actions. 2024-2025.
14. Centers for Medicare & Medicaid Services. Medicare Part D formulary guidance on compounded medications. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.